30 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Developing an anti-Myc cell-penetrating peptide for cancer treatment (GBM-CPP)
Date du début: 1 août 2016, Date de fin: 31 juil. 2017,
Despite ever-increasing investments in the development of new treatments, many cancers remain incurable. One reason is that most current therapies target redundant functions around which tumour cells can build resistance. We focus instead on a unique and essential cellular function: the Myc oncogene, deregulated in more than 70% of human cancers. Targeting Myc has long been considered unfeasible b ...
Voir le projet
2
Participants partenaires
TERMINÉ
high-throughput screening for high-grade glioma (HTS-4-GBM)
Date du début: 1 sept. 2014, Date de fin: 31 août 2016,
Glioblastoma is the most common and most malignant form of primary brain tumour. It affects both children and adults and remains virtually incurable. As a result, it is a leading cause of cancer-related deaths and more effective therapeutic strategies are urgently needed. Herein, I propose to use an innovative methodology combining high-throughput drug screening, pathway analysis and functional ge ...
Voir le projet
1
Participant partenaire
TERMINÉ
Job Developer: From Job Creation to Competence Development
Date du début: 1 sept. 2015, Date de fin: 31 août 2018,
...eans of the application of the instruments „employment radar“ and „talent diagnosis“ – resp. the country-specific adaptation of these instruments – developed by SHS/minipreneurs GBM. Young adults are encouraged and enabled by the support and under the tutelage of a skilled/trained „job developer“ to detect employment opportunities, to create jobs on their own as well as to deduce the respective di ...
Voir le projet
9
Participants partenaires
TERMINÉ
Biochemical and functional studies of lineage-specific transcription factor complexes in glioblastoma-derived stem cells (GNS_cells)
Date du début: 1 juin 2011, Date de fin: 31 mai 2013,
Cancer is one of the leading causes of death worldwide. Brain cancers, in particular glioblastoma (GBM), have incredibly poor prognosis and there are currently few effective treatments. Our understanding of the molecular defects associated with cancer has significantly increased over the past decade. Many of the commonly disrupted genes control cell proliferation and survival pathways. However, it ...
Voir le projet
1
Participant partenaire
TERMINÉ
A paradigm shift in cancer therapy – using mitochondria-powered chemiluminescence to non-invasively treat inaccessible tumours (Lumiblast)
Date du début: 1 oct. 2016, Date de fin: 31 mars 2021,
Brain cancers such as glioblastoma multiforme (GBM) are practically incurable due to their location, invasiveness and highly aggressive nature. The use of light-based treatments of GBM by activating tumor-localized photosensitizers, such as in photodynamic therapy (PDT) has been clinically evaluated, but with limited success. This is mainly due to the limited penetration of light into tissue and t ...
Voir le projet
6
Participants partenaires
TERMINÉ
Theranostic Injectable Hydrogel for Glioblastoma (HyGlio)
Date du début: 30 sept. 2016, Date de fin: 29 sept. 2019,
Glioblastoma multiforme (GBM) is the most frequent brain tumor in adults and is characterized by invariably fatal prognosis. Although the incidence of GBM is less than 10 to 100,000, the median survival of approximate 1 year from diagnosis makes it a considerable socio-economic burden. The presence of biological barriers for effective drug transport to the brain, the strong migrating-ability of th ...
Voir le projet
1
Participant partenaire
TERMINÉ
GlioDx - Blood platelet-based monitoring and treatment optimisation for glioblastoma patients (GlioDx)
Date du début: 1 sept. 2016, Date de fin: 28 févr. 2018,
Glioblastoma (GBM) is a devastating primary brain cancer which affects about 230.000 people annually. The choice for treatment depends on the subtype of GBM. An accurate detection of tumour subtype is therefore essential for a personalised targeted treatment. Diagnosis, classification and treatment monitoring occurs currently by radiology and repeated invasive biopsies. There is a need for non-inv ...
Voir le projet
1
Participant partenaire
TERMINÉ
Pericyte-derived tumor stroma – a target for cancer therapy (PERICYTEStroma)
Date du début: 1 oct. 2016, Date de fin: 30 sept. 2018,
...his characterization of heterogeneity is important to distinguish stroma-forming pericytes from the non-forming ones and from tumor cell-derived pericytes as described in Glioblastoma multiforme (GBM). Furthermore, by using combinations of pericyte reporter mice with genetic tools to manipulate pathways regulating cell proliferation and recruitment within specific pericyte subpopulations, I aim to ...
Voir le projet
1
Participant partenaire
TERMINÉ
Feasibility study of a novel treatment for cancer based on a recombinant peptide therapy (PEPTO1)
Date du début: 1 mars 2016, Date de fin: 31 juil. 2016,
...devices. Peptomyc’s first mission is to take the first drug product (OMO-101) to completion of a successful phase I/II clinical trial, demonstrating safety and efficacy initially in glioblastoma (GBM) patients. Upon completion of phase I/II, Peptomyc plans to reach a licensing deal with a pharmaceutical company, to take care of further development and commercialization of OMO-101. In the feasibili ...
Voir le projet
1
Participant partenaire
TERMINÉ
Alphaviral Immunotherapy against Glioblastoma (AVITAG)
Date du début: 1 mai 2016, Date de fin: 30 avr. 2018,
Alphaviral Immunotherapy against GlioblastomaGlioblastomas (GBM) are the most frequent type of primary brain tumours with no treatment or cure available. Despite the current standard care, GBMs remain 100% fatal with median survival of patients for only 12 - 15 months. Thus, there is an urgent need for novel effective therapies.Among the emerging new therapeutic approaches is oncolytic virotherapy ...
Voir le projet
1
Participant partenaire
TERMINÉ
Targeting Glioblastoma Reprogrammed Stem Cells (Tumor Reprogramming)
Date du début: 1 mars 2015, Date de fin: 28 févr. 2019,
Glioblastoma multiforme (GBM) is both the most common and lethal primary malignant brain tumor. In the last century we have accumulated tremendous amounts of data on this type of cancer, but we have achieved very little improvement in its treatment. Despite decades of concerted effort and advances in surgery, radiation and chemotherapy, the median survival is 15 months. The inadequate progress in ...
Voir le projet
1
Participant partenaire
TERMINÉ
Understanding tumour resistance: Receptors and signalling pathways that can lead the race against tumour angiogenesis (ALTangioTARGET)
Date du début: 16 mars 2015, Date de fin: 15 août 2017,
...or (VEGF) therapies, such as bevacizumab, inhibit VEGF angiogenic actions and are increasingly used in the clinic as anticancer regimens for a variety of tumours, among which glioblastoma multiforme (GBM), the most lethal and angiogenic brain tumour, characterized by a high degree of heterogeneity. However, resistance to anti-angiogenic therapy, which leads to ineffectiveness of the existing drugs ...
Voir le projet
1
Participant partenaire
TERMINÉ
Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour’s immune system. (CSC-IS)
Date du début: 1 juil. 2015, Date de fin: 31 déc. 2016,
...nt observed in the past years in the development of new treatments, there is still lack on an effective treatment in many tumour types. In particular, the median survival for glioblastoma multiforme (GBM), a high-grade brain tumour affecting 23,000 patients a year in US and EU, is 14 months and its 5-yr survival less than 5%. It is therefore urgent to develop more effective treatments against this ...
Voir le projet
2
Participants partenaires
TERMINÉ
Validation of a conceptually new treatment for glioblastoma multiforme with an IP protected small molecule (GlioVac)
Date du début: 1 mars 2015, Date de fin: 31 août 2016,
Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer with marginal life expectancy even with the most aggressive available therapy. We have identified a previously unanticipated vulnerability of GSCs which when targeted, leads to a rapid and complete cell death of all tumor cells isolated from nine different patients diagnosed with GBM. The cellular mechanism has been identifi ...
Voir le projet
1
Participant partenaire
TERMINÉ
High Energy Solar Particle Events foRecastIng and Analysis (HESPERIA)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2017,
...oncepts (UMASEP, REleASE). At the same time it will advance our understanding of the physical mechanisms that result into high-energy solar particle events (SEPs) exploiting novel datasets (FERMI/LAT/GBM; PAMELA; AMS) and it will explore the possibility to incorporate the derived results into future innovative space weather services. In order to achieve these goals HESPERIA will exploit already av ...
Voir le projet
9
Participants partenaires
TERMINÉ
Engineering Discoidal Polymeric Nanoconstructs for the Multi-Physics Treatment of Brain Tumors (POTENT)
Date du début: 1 juil. 2014, Date de fin: 30 juin 2019,
"Despite significant advances in chemotherapy, the effective treatment of malignant masses via systemically injectable agents are still limited by insufficient accumulation at the biological target (
Voir le projet
1
Participant partenaire
TERMINÉ
Identification of TRAIL sensitivity/resistance mechanisms and searching for novel TRAIL-sensitizing agents in Glioblastoma Multiforme (TRIGBM)
Date du début: 1 sept. 2013, Date de fin: 31 août 2017,
"The overall goal of this proposal is to explore the molecular basis of TRAIL-response in an aggressive brain cancer, Glioblastoma Multiforme (GBM), and identify new reagents that will augment the TRAIL response of GBMs. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL), emerged as a prime candidate for cancer treatment due to its tumor-specificity, however its clinical success is li ...
Voir le projet
1
Participant partenaire
TERMINÉ
Glioblastoma Inhibition: Targeting Tumour-derived Extracellular-Vesicle Driven Cell-Recruitment (GLITTER)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,
"Glioblastomas (GBMs) are malignant brain tumours and among the most aggressive human cancers. GBMs patients have an extremely poor survival rate due to a complete absence of adequate therapies capable of efficiently targeting GBM cells inside the brain. Recently, we demonstrated that GBM cells release pro-tumoural extracellular vesicles (EVs) into the bloodstream, which emerged as important inter ...
Voir le projet
1
Participant partenaire
TERMINÉ
DNA Damage Response (DDR) signaling in tumor formation and therapeutic resistance of gliomas (GLIDD)
Date du début: 1 juil. 2014, Date de fin: 30 juin 2018,
"The gliomas are a large group of brain tumors and Glioblastoma Multiforme (GBM) is the most common and lethal primary central nervous system (CNS) tumor in adults. Despite the recent advances in treatment modalities, GBM patients generally respond poorly to all therapeutic approaches and prognosis remain dismal. Standard therapy for GBMs includes resection of the tumor mass, followed by concurren ...
Voir le projet
1
Participant partenaire
TERMINÉ
The histone H3.3 variant in brain cancer pathogenesis (H3.3CANCER)
Date du début: 1 mai 2014, Date de fin: 30 avr. 2019,
...genetic reprogramming is a hallmark of brain cancer. Remarkably, driver mutations of the histone H3.3 variant and its loading machinery have been recently found in paediatric glioblastoma multiforme (GBM), a devastating neoplasm originating from transformed neural precursors. Thus, the very basic building blocks of chromatin can be mutated in cancer.The present challenge is to define at which leve ...
Voir le projet
1
Participant partenaire
TERMINÉ
Glioma Actively Personalized Vaccine Consortium (GAPVAC)
Date du début: 1 nov. 2012, Date de fin: 31 janv. 2017,
"Glioblastoma (GBM) is a rare (2-3 incidences in 100,000) and fatal disease. Each year, approximately 13,000 new cases of GBM are diagnosed in Europe. The 5-year survival rate of this highly aggressive tumor entity under conventional therapy is less than 6%. Currently available therapeutic options neglect the individuality of each patients’ disease and only temporarily influence tumor progression ...
Voir le projet
13
Participants partenaires
TERMINÉ
Molecular and Cellular Mechanisms of Glioma Genesis (Gliomagenesis)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
Glioblastoma (GBM) is the most aggressive form of glioma, the most common primary brain cancer in adults. GBM is highly resistant to standard radiotherapy and chemotherapy treatments and thus represents a leading cause of cancer-related death worldwide. Although many genetic alterations have been identified for GBM, its histogenesis is still poorly understood. The relative contribution of each gen ...
Voir le projet
1
Participant partenaire
TERMINÉ
Targeting Cancer Stem Cells (CSC) for the development of more effective treatments to cure cancer patients (Anti-CSC)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2013,
...nt observed in the past years in the development of new treatments, there is still lack on an effective treatment in many tumour types. In particular, the median survival for glioblastoma multiforme (GBM), a high-grade brain tumour affecting 23,000 patients a year in US and EU, is 14 months and its 5-yr survival less than 5%. It is therefore urgent to develop more effective treatments against this ...
Voir le projet
2
Participants partenaires
TERMINÉ
GENOMIC AND TRANSCRIPTIONAL ANALYSIS OF GLIOBLASTOMA MICROENVIRONMENTAL CELLULAR SUBSETS USING ANTIBODY MICROARRAYS (Crosstalk in GBMs)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2014,
The applicant is an experienced researcher with the objective of completing comprehensive training in translational research on Glioblastoma Multiforme (GBM), one of the most common malignant and lethal primary brain tumor of adults, with the final aim of disposing of personalized therapeutic protocols for GBM and cancer patients. The project is based on the finding that human tumors, particularly ...
Voir le projet
1
Participant partenaire
TERMINÉ
Development of tumor penetrating peptides for glioma targeting (GliomaDDS)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,
...eavage site), which can be rearranged to yield peptides of novel specificities.Our goal is to develop TPP platform for delivery of co-administered drugs to the deadliest brain tumor – glioblastoma (GBM). High-grade glioma is a target that is particularly evasive and well-suited for tissue penetrative drug delivery. We will develop glioma-specific TPP (gTPP) by combination of in vivo and ex vivo ph ...
Voir le projet
1
Participant partenaire
TERMINÉ
Role of Notch signaling pathway in Glioma Stem Cells (Notch pathway in GSC)
Date du début: 1 juin 2012, Date de fin: 20 sept. 2014,
Glioblastoma multiforme (GBM) is the most common malignant intracranial tumor in adults. Despite the knowledge of the genetic alterations associated to GBM and the improvement in neurosurgery and chemo- and radiotherapy, little improvement has been achieved in the median survival. Recently, glioma stem cells (GSCs) have been identified to be responsible of the origin, recurrence and drug resistanc ...
Voir le projet
2
Participants partenaires
TERMINÉ
Identification of the genetic and/or epigenetic events that lead to mesenchymal transformation in glioblastoma (GAMNG)
Date du début: 1 oct. 2010, Date de fin: 6 juil. 2014,
"Glioblastoma multiforme (GBM) is the most malignant type of brain tumor in adults with a median survival of one year. The hallmarks of GBM are invasion and neo-angiogenesis. Recently, gene expression studies have established that overexpression of a “mesenchymal” gene signature co-segregate with the poor-prognosis group of glioma patients. We have revealed that two transcription factors, Stat3 an ...
Voir le projet
1
Participant partenaire
TERMINÉ
Interruption of protein-protein interaction and network to cancer biomarkers and therapeutic targets (PPI-MARKER)
Date du début: 1 août 2010, Date de fin: 31 juil. 2014,
... will use prostate cancer and gliomas as models. Prostate cancer is the most common form of cancer and the leading cause of cancer death among men in the developed countries. Glioblastoma multiforme (GBM) is the most common and most aggressive type of primary brain tumor and it GBM accounts for 52% of all primary brain tumor cases. Novel markers and therapeutic targets are still needed for these t ...
Voir le projet
3
Participants partenaires
TERMINÉ
Flexible and Mobile Economic Processing Technologies (FAME)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
FAME aims to increase the competiveness of the mining of European mineral resources and to stimulate more private engagement and investment and thus business development with the potential to maintain and create high quality jobs within the EU28. The focus and a principal aim is to enhance mineral processing and mining skills within Europe. A medium to long term aim is to reduce the reliance of Eu ...
Voir le projet
18
Participants partenaires
TERMINÉ
Welding national industries together across Europe : The project has developed a European certification system for the welding industry. People in this sector will benefit from greater worker mobility thanks to the project, which creates greater transparency in welding skills. This project started in 2002 and lasted 24 months.
Voir le projet